

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Atherosclerosis; inflammation; ischemia/reperfusion injury; sepsis	Sphingosine 1-phosphate receptor 2 (S1PR2; S1P2; EDG5)	<p>Mouse studies suggest inhibitors of S1PR2 could help treat inflammatory vascular disorders. In mice, an S1PR2 antagonist decreased lipopolysaccharide (LPS)-induced increases in inflammation and vascular permeability compared with saline. In the same model, <i>S1pr2</i>-deficient mice showed lower expression of inflammation and coagulation mediators than wild-type mice in response to LPS. Next steps could include evaluating S1PR2 inhibitors in preclinical models for inflammatory vascular disorders such as atherosclerosis and ischemia/reperfusion injury.</p> <p>SciBX 6(26); doi:10.1038/scibx.2013.668 Published online July 11, 2013</p>	Unpatented; licensing status not applicable	<p>Zhang, G. <i>et al. Blood</i>; published online May 30, 2013; doi:10.1182/blood-2012-11-467191 Contact: Teresa Sanchez, Harvard Medical School, Boston, Mass. e-mail: tsanchez@bidmc.harvard.edu</p>